$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
西米普利单抗(Cemiplimab)的用法用量:用药指南,剂量调整,特殊人群用药
2025-10-19 11:44:20
Check Details
宗格替尼(Zongertinib)的详细说明书:作用与功效,用法用量,副作用,注意事项等
2025-10-19 11:44:20
Check Details
宗格替尼(Zongertinib)的副作用和不良反应
2025-10-19 11:44:20
Check Details
FDA批准西米普利单抗(Cemiplimab)作为首个用于晚期基底细胞癌患者的免疫疗法
2025-10-19 11:44:20
Check Details
FDA批准西米普利单抗(Cemiplimab)用于晚期皮肤鳞状细胞癌
2025-10-19 11:44:20
Check Details
宗格替尼(Zongertinib)是治疗什么疾病的
2025-10-19 11:44:20
Check Details
宗格替尼(Zongertinib)的注意事项和药物相互作用
2025-10-19 11:44:20
Check Details
宗格替尼(Zongertinib)国内价格是多少
2025-10-19 11:44:20
Check Details
2025年宗格替尼(Zongertinib)最新价格是多少钱一盒?
2025-10-19 11:44:20
Check Details
宗格替尼(Zongertinib)怎么购买
2025-10-19 11:44:20
Check Details
宗格替尼(Zongertinib)的用法用量
2025-10-19 11:44:20
Check Details
宗格替尼(Zongertinib)中文说明书
2025-10-19 11:44:20
Check Details
1
2
...
2956
2957
2958
2959
2960
2961
2962
...
4155
4156
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Onset Timeline and Efficacy Assessment of Margetuximab plus Chemotherapy in HER2-Positive Metastatic Breast Cancer
2
Avutometinib Plus Defactinib: A Precision Therapy for KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer
3
Vemurafenib (Zelboraf) Complete Medication Guide
4
Durvalumab Safety Profile: Managing Immune-Related Adverse Events (irAEs) in Clinical Practice
5
Zolbetuximab Combination Therapy: Global Efficacy and Safety Profile in CLDN18.2-Positive Advanced Gastric Cancer
6
Managing Mitotane Resistance in Adrenocortical Carcinoma: Strategies and Global Options
7
Trametinib & Dabrafenib in 2026: A Global Guide to Treating BRAF-Mutant Cancers
8
A Guide to Safely Stopping Mitotane: Why Tapering is Essential and How to Manage
9
Pemigatinib Efficacy: Significantly Improving Survival in FGFR2-Fusion Cholangiocarcinoma
10
Erlotinib: Targeting EGFR Mutations to Precisely Inhibit Non-Small Cell Lung Cancer Growth
11
Tofacitinib: The Role and Considerations of an Oral JAK Inhibitor in Autoimmune Disease Treatment
12
Tucatinib: Redefining the Treatment Landscape for HER2-Positive Cancers with High Selectivity